By Cheng Liu, K. John Morrow Jr.
Addressing an important want through describing the technological know-how and strategy concerned to advance biosimilars of monoclonal antibody (mAb) medicinal drugs, this e-book covers all facets of biosimilar improvement: preclinical, medical, regulatory, manufacturing.
• Guides readers in the course of the complicated panorama concerned with constructing biosimilar models of monoclonal antibody (mAb) drugs
• Features move charts, tables, and figures that truly illustrate strategies and makes the booklet understandable and accessible
• Includes a evaluation of FDA-approved mAb medicinal drugs as a short connection with evidence and worthy information
• Examines new applied sciences and methods for bettering biosimilar mAbs
Read Online or Download Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development PDF
Similar immunology books
This finished, authoritative treatise covers all facets of mucosal vaccines together with their improvement, mechanisms of motion, molecular/cellular facets, and functional purposes. The contributing authors and editors of this exclusive booklet are rather well identified of their respective fields. Mucosal Vaccines is prepared in a distinct structure within which uncomplicated, medical, and useful points of the mucosal immune process for vaccine improvement are defined and mentioned.
Jeder Mensch verfügt über ein leistungsfähiges Immunsystem, das ihn sicher durch die ständig lauernden Gesundheitsgefahren der Umgebung leitet. Entgleist diese körpereigene Abwehr oder läßt ihre Einsatzfreude nach, wird der Mensch krank. Arnold Hilgers und Inge Hofmann zeigen, wie die moderne Medizin die Geheimnisse und methods dieser inneren Schutztruppen entschlüsselt hat und vielen Feinden des Immunsystems auf die Schliche gekommen ist.
This quantity is a realistic biochemical consultant to the Enzyme-Linked Immunosorbent Assay (ELISA), used to notice a objective substance in a liquid pattern. The ELISA is a crucial and everyday diagnostic instrument in drugs, animal overall healthiness, botany and caliber insurance methods in nutrients and beverage creation.
This quantity presents the entire crucial protocols which are presently used to check the immune synapse. Chapters within the Immune Synapse: tools and Protocols hide equipment for the research of the dynamics of immune synapse meeting, site visitors on the immune synapse, new excessive answer imaging, biophysical and computational tools for the examine of the immune synapse, effector immune synapses, B mobilephone, NK and mast telephone immune synapses, and immune interactions in vivo.
Extra resources for Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development
From Columbia Law School. K. John Morrow, Jr. A molecular biologist, K. John Morrow, Jr. is president of Newport Biotechnology Consultants. He specializes in writing and consulting in the area of immunology, with a focus on antibody technology. D. from the University of Washington and did postdoctoral studies in Italy at the Università degli Studi di Pavia and at the Fox Chase Cancer Center in Philadelphia. He has been employed at several universities as a faculty member including Texas Tech and Kansas University and has also worked in the private sector.
In Chapter 16, Rafiq Islam reviews the development of bioanalytical tests of biosimilar antibodies, including glycosylation pattern, ADCC/CDC activity, and FcγR binding profile. Critical features of such characterizations are the test results required to demonstrate similarity to the original product, as stated in the regulatory guidelines issued by the FDA and EMEA. Drs. João Fonseca and João Gonçalves cover preclinical and clinical development of biosimilar antibodies in Chapter 17. They touch on a recurrent theme in this book: that biosimilars offer a highly attractive strategy for reducing medical costs and increasing accessibility to targeted biologic therapies.
Projan joined Wyeth in 1993 as a group leader in anti‐infectives research. He became an associate director of Bacterial Genetics in January of 1997 and then director of Antibacterial Research in June of 1998. In May of 2003 he was appointed assistant vice president of Protein Technologies, and in September 2004 he was promoted to vice president and head of the newly created Department of Biological Technologies which was responsible for delivery of novel biologics to development (this group is now part of Pfizer).